SUMMARYIndividuals de®cient in C3 or a late complement component are susceptible to recurrent meningococcal infections. Since they experience meningococcal episodes mostly with uncommon meningococcal serogroups, vaccination with a tetravalent vaccine containing A, C, Y and W135 polysaccharides has been suggested. We vaccinated a cohort of two C3 and 17 late complement component-de®cient (LCCD) patients, revaccinated them 7 years later and investigated the development of their IgG antibodies to the capsular polysaccharides of the meningococcal vaccine. Seven years after the ®rst vaccination levels of IgG antibodies declined compared with the levels present at 6 months after the ®rst vaccination, but were still at least four times higher than before vaccination. Levels of antibodies to Y polysaccharide in serum of complement-de®cient patients were rather low but they did not differ signi®cantly from those in serum of healthy non-related controls (P 0´07). Three months after the second vaccination IgG antibodies against all polysaccharides increased, exceeding those measured at 6 months after the ®rst vaccination. In the 8 years of observation after the ®rst vaccination two new meningococcal infections with strains related to the vaccine (serogroup Y strains) occurred in two patients, 3´5 and 5 years after the ®rst vaccination. Our ®ndings show that high IgG antibody levels against the tetravalent meningococcal polysaccharide vaccine were reached after revaccination of two C3 and 17 LCCD individuals 7 years after the ®rst vaccination. Whether revaccination should be required within a period shorter than 7 years is discussed, since two vaccinees developed meningococcal disease to vaccine serogroup Y.